# I-01 — Execution Readiness & Shadow Mode Validation

## 1. Purpose and Scope
The purpose of this document is to define the architectural and governance requirements for Phase I (Execution Readiness & Shadow Mode Validation). This phase serves as a final safety and validation gate before any automated or semi-automated agent execution is permitted to interact with external systems or production data in an active capacity. The scope is limited to defining "Execution Readiness" and the "Shadow Mode" operating environment.

## 2. Relationship to Phases E–H
Phase I builds upon the foundational work established in previous phases:
- **Phase E (Simulation)**: Provides the sandboxed execution environment.
- **Phase F (Audit & Evidence)**: Provides the trace and logging infrastructure.
- **Phase G (Execution Adapters)**: Provides the technical interfaces for action.
- **Phase H (Execution Simulation Dry Run)**: Provides the end-to-end simulation results that inform the validation signals required for Phase I.

## 3. Definition of “Execution Readiness”
"Execution Readiness" is defined as a state where a specific agent or system component has met all safety, performance, and governance criteria required to move from pure simulation into a controlled Shadow Mode. It implies that the system is technically capable of execution, but remains inhibited by governance gates.

## 4. Shadow Mode Definition (no external side effects)
"Shadow Mode" is an operational state where agent logic processes real-time production triggers and generates proposed actions, but these actions are **never** executed against external systems, production databases, or patient-facing interfaces.
- **Strict Isolation**: Shadow Mode execution MUST NOT result in any external side effects (e.g., no emails sent, no database writes, no API calls to third-party services).
- **Parallel Processing**: Shadow Mode runs in parallel with existing human-led or legacy processes to compare agent-generated outputs against actual outcomes.

## 5. Authority and Approval Model
Authority to enter Shadow Mode is granted on a per-agent and per-use-case basis. 
- **Approval Body**: Transition to Shadow Mode requires formal sign-off from the Clinical Safety Board, Technical Architecture Committee, and Compliance Officer.
- **Revocation**: Authority can be revoked immediately if validation signals indicate drift or safety concerns.

## 6. Validation Signals and Evidence Required
Transition to and exit from Shadow Mode requires the following evidence:
- **Zero-Failure Simulation Runs**: Evidence of 100% success rate in Phase H dry runs.
- **Drift Analysis**: Quantitative comparison of Shadow Mode outputs against human/legacy outcomes.
- **Latency & Performance Logs**: Confirmation that the execution path meets production performance requirements.
- **Audit Completeness**: Verification that every Shadow Mode action is captured in the Phase F audit store.

## 7. Failure, Drift, and Mismatch Handling
- **Drift Detection**: Any significant delta between a Shadow Mode proposal and the human-led outcome must trigger an automatic review.
- **Failure Logging**: All execution failures in Shadow Mode must be categorized and remediated before further progression.
- **Mismatch Analysis**: A formal process for analyzing why an agent's proposed action differed from reality.

## 8. Patient, Clinician, Operator Guarantees
- **Safety First**: No patient care shall be impacted by the system while in Phase I.
- **Zero-Interference**: System performance for clinicians and operators must not be degraded by the overhead of Shadow Mode processing.
- **Privacy Preservation**: All data handled in Shadow Mode remains subject to existing HIPAA and security protocols.

## 9. Explicit Prohibitions
- **NO Active Execution**: Writing to production databases or calling external APIs with side effects is strictly prohibited.
- **NO Patient Communication**: Sending messages, notifications, or instructions to patients is strictly prohibited.
- **NO Bypassing Gates**: Manual override of safety inhibitors is strictly prohibited.

## 10. Out of Scope
- Implementation of active execution adapters.
- Authorization for production live-fire execution.
- Modifications to core clinical workflows.

## 11. Exit Criteria for Phase I
- Successful completion of a pre-defined period of Shadow Mode operation with zero critical mismatches.
- Formal "Execution Readiness Report" signed by all relevant governance bodies.
- Verification of rollback and compensation mechanisms (from Phase F) in a simulated production environment.

## 12. Closing Governance Statement
“This document authorizes understanding and governance alignment only. It does not authorize execution.”
